B01AD · Blood and blood-forming organs
Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
Indications
Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG is indicated for the thrombolytic treatment of suspected myocardial infarction with persistent ST elevation or recent left Bundle Branch Block within 6 hours after the onset of acute myocardial infarction (AMI) symptoms.
Composition
- Active substance
- tenecteplase
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG
- Active substance
- tenecteplase
- ATC code
- B01AD
- Therapeutic area
- Myocardial Infarction
- Marketing authorisation holder